Literature DB >> 8849345

Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.

N Goel1, D T Ulrich, E W St Clair, J A Fleming, D H Lynch, M F Seldin.   

Abstract

OBJECTIVE: To determine whether elevated soluble Fas/APO-1 (sFas/APO-1) levels are associated with either autoimmune disease or evidence of flares in autoimmune disease.
METHODS: Thirty-seven serum samples were retrospectively obtained from normal controls and patients with laboratory evidence of autoimmune disease activity. These samples were assayed for sFas/APO-1 levels by an enzyme-linked immunosorbent assay, and hospital medical records were retrospectively reviewed for clinical and laboratory characteristics of the patients.
RESULTS: Soluble Fas/APO-1 levels did not correlate with clinical diagnoses or laboratory abnormalities. The mean and range of sFas/APO-1 levels were similar in systemic lupus erythematosus patients (including those with active disease), patients with other autoimmune diseases, and normal controls.
CONCLUSION: These data strongly suggest that measurement of sFas/APO-1 levels is unlikely to hold clinical value or play a role in the pathogenesis of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8849345     DOI: 10.1002/art.1780381206

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.

Authors:  T Fujihara; T Takeuchi; K Tsubota; N Kayagaki; H Yagita; K Okumura; T Abe
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

2.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.

Authors:  Y Tokano; S Miyake; N Kayagaki; K Nozawa; S Morimoto; M Azuma; H Yagita; Y Takasaki; K Okumura; H Hashimoto
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

3.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.

Authors:  J Wu; J Wilson; J He; L Xiang; P H Schur; J D Mountz
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

4.  Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives.

Authors:  M W van der Linden; T van Lopik; L A Aarden; R G Westendorp; T W Huizinga
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

5.  Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Authors:  Marta Christensson; Erna Pettersson; Kjell Eneslätt; Birger Christensson; Johan Bratt; Solbritt Rantapää-Dahlqvist; Karl-Gösta Sundqvist
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

6.  The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.

Authors:  Aşkin Ateş; Gülay Kinikli; Murat Turgay; Murat Duman
Journal:  Clin Rheumatol       Date:  2004-05-15       Impact factor: 2.980

7.  Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.

Authors:  A Tomokuni; T Aikoh; T Matsuki; Y Isozaki; T Otsuki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.